Home Business Kerrisdale Capital on the China Medical Short Saga

Kerrisdale Capital on the China Medical Short Saga

Advertisement Disclosure: When you purchase through our sponsored links, we may earn a commission from our partners. By using this website you agree to our T&Cs.

Kerrisdale Capital on the China Medical Short Saga

The famous short selling hedge fund, Kerrisdale Capital, is out with its Q3 letter.

Kerrisdale Partners LP achieved a quarterly return, net to investors, of 9.1% for the quarter ended September 30, 2012. The S&P 500 index returned 6.4% during that time.
Since inception, the fund has achieved a return, net to investors, of 742.3%. The S&P 500 index has returned 67.6% during that time.
They detail an extremely interesting story about shorting of a potential fraud in the letter:

Today, the China Medical Technologies, Inc. (PINK:CMEDQ)  saga is over, and we can do an appropriate post-mortem. We established our initial short position in China Medical in the fourth quarter of 2012, when Glaucus Research published a report alleging that China Medical Technologies, Inc. (PINK:CMEDQ) management was committing fraud. We generated some returns from the position and at the end of the year assumed that China Medical would just become one of the many Chinese fraudcaps that populated our general short basket at the time.

Kerrisdale Capital Q3

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Editor
Investing

Which Stocks Should You Buy, and Sell, in 2026?

Dave Kovaleski5 months

Also, the 3 sectors that Wall Street analysts are most bullish about. The usual suspects dominated in 2025 as both the Communication Services and Information Technology sectors helped boost the...